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b2-Adrenergic Receptor Antagonist Accelerates Skin Barrier
Recovery and Reduces Epidermal Hyperplasia Induced by
Barrier Disruption
Mitsuhiro Denda, Shigeyoshi Fuziwara, and Kaori Inoue
Shiseido Research Center,Yokohama, Japan
E¡ects of topical application of adrenergic receptor
agonists and antagonists on epidermal barrier repair
rate after barrier disruption were studied. Agonists and
antagonists of b1-adrenergic receptor did not a¡ect the
barrier repair rate. On the other hand, b2-adrenergic re-
ceptor agonists, procaterol and alprenol, delayed barrier
recovery and the b2 receptor antagonist, ICI-118551,
blocked the delay. Moreover, topical application of ICI-
118551 or b1,2 receptor antagonist, clenbuterol alone ac-
celerated barrier recovery. Antagonists of a1 and a2 re-
ceptors did not a¡ect barrier recovery. The delay of
barrier repair induced by prodaterol hydrochloride was
blocked by a voltage-gated calcium channel blocker,
verapamil or nifedipine. In cultured human keratino-
cytes, procaterol increased the intracellular calcium
concentration and the increase was blocked by ICI-
118551 and also by verapamil or nifedipine. Topical ap-
plication of ICI-118551 partially blocked the epidermal
hyperplasia induced by acetone treatment under low
environmental humidity. These results suggest that the
b2-adrenergic receptor is speci¢cally associated with
skin barrier homeostasis. Key words: calcium/epidermis/
keratinocyte/verapamil/voltage-gated calcium channel. J In-
vest Dermatol 121:142 ^148, 2003
P
revious studies have suggested that ion gradation in the
epidermis is strongly associated with the barrier repair
system (Menon et al, 1994; Mauro et al, 1998; Denda
et al, 2000a). When the calcium concentration in the
upper epidermis increases by sonophoresis, lamellar
body secretion is prevented (Menon et al, 1994). Lee et al (1994)
demonstrated that voltage-gated calcium channel blockers pre-
vent the delay of barrier repair induced by increased extracellular
calcium concentration. These results suggest that the calcium £ux
into the keratinocytes perturb the lamellar body secretion and
barrier repair, and blocking the calcium £ux prevents the delay
of the barrier recovery; however, the type of the channel involved
in skin barrier homeostasis has not been found yet. Previously,
expression of an adrenergic receptor and its role in intracellular
calcium dynamics in the keratinocyte has been reported (Koizu-
mi et al, 1991; Schallreuter et al, 1995; Steinkraus et al, 1996). More-
over, epinephrine and norepinephrine are associated with
emotional conditions (Lorimer et al, 1976) and we previously de-
monstrated that psychologic stress in£uenced skin barrier home-
ostasis (Denda et al, 1998a, 2000b). Thus, we hypothesized that
adrenergic receptors play an important part in skin barrier home-
ostasis. In this study, we demonstrated that the e¡ects of adrener-
gic receptor agonists and antagonists on the barrier repair process
after barrier disruption.We also evaluated the e¡ect of verapamil
and nifedipine on the barrier recovery rate together with that of
an adrenergic receptor agonist. Then, we studied the e¡ect of
adrenergic receptor agonist and antagonist in intracellular cal-
cium dynamics of cultured human keratinocytes. Finally, we de-
monstrated the e¡ects of these reagents on epidermal
proliferation induced by barrier disruption under low environ-
mental humidity.
MATERIALS ANDMETHODS
Materials All experiments were performed on 7 to 10 wk old male
hairless mice (HR-1, Hoshino, Japan). All procedures, including the
measurement of skin barrier function, disruption of the barrier, and
application of test sample, were carried out under anesthesia. All
experiments were approved by the Animal Research Committee of the
Shiseido Research Center in accordance with the National Research
Council Guide (National Research Council, 1996). Only cultured human
keratinocytes, taken from neonates with patental consent, were used.
Keratinocytes were treated in accordance with Helsinki, principles.
Xamoterol hemifumarate, betaxolol hydrochloride hemihydrate,
procaterol hydrochloride, ICI-118,551, corynanthin, and rawolscine
hydrochloride were purchased from Tocris Cookson Ltd. (Avonmouth,
UK).Verapamil and nifedipine were purchased fromWako (Osaka, Japan).
Aiprenolol, clenbuterol, and FPL64176 were purchased from Sigma (St
Louis, Missouri).
Cutaneous barrier function Permeability barrier function was
evaluated by measuring transepidermal water loss (TEWL) with an
electric water analyzer (Meeco, Warrington, Pennsylvania), as described
previously (Denda et al, 1998b). For barrier recovery experiments, both
sides of £ank skin were treated with repeated tape stripping until the
TEWL reached 7 to 10 mg per cm2 per h, as described previously (Denda
et al, 1998a). Immediately after barrier disruption, 100 mL of an aqueous
solution containing each reagent (1 mM) or water alone (control) was
applied to the treated area (2 3cm2).We applied one reagent on one side
of £ank and another reagent or water as a control was applied on the other
side of the £ank. The areas were covered with a plastic membrane for 15
min and the membrane was removed. Two points on one side of the £ank
were measured and four to 12 mice were used to evaluate the e¡ects of each
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treatment. TEWLwas then measured over the same sites exactly 1, 3, and 6
h after barrier disruption. Barrier disruption was always done between
07.00 h and 8.00 h and then the barrier recovery rate was evaluated to
avoid the deviation of the results by a circadian rhythm (Denda and
Tsuchiya, 2000). The barrier recovery results are expressed as percent of
recovery, because of variations from day to day in the extent of barrier
disruption. In each animal, the percentage of recovery was calculated by
the following formula: (TEWL immediately after barrier disruption ^
TEWL at indicated time point)/(TEWL immediately after barrier
disruption ^ baseline TEWL) 100%.
Immunohistochemistry Polyclonal anti-serum and blocking peptide
of b2-adrenergic receptor were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, California). It was rabbit polyclonal
antibody raised against a peptide mapping at the c-terminus of the b2-
adrenergic receptor of mouse origin. The anti-serum was diluted 500:1
with blocking solution, i.e., 3% bovine serum albumin/phosphate-
bu¡ered saline (PBS) solution containing 10% heat-inactivated goat
serum and 0.4% Triton X-100. Fluorescence secondary antibody was
purchased from Molecular Probes, Inc. (Eugene, Oregon; Alexa Fluor
589, anti-rabbit IgG conjugate). The secondary antibody was also diluted
500:1 with the blocking solution. The blocking peptides were
reconstituted with 200 mL of PBS solution. For blocking the antibody/
antigen binding, the blocking peptide was used at the ¢nal concentration
10 mM as suggested by the manufacturer. A 5 mm frozen skin section was
¢xed with ^201C methanol for 10 min and soaked in PBS solution. Then
the section was blocked with blocking solution for 1 h at room
temperature. The section was covered with diluted anti-serum solution
and kept at 41C overnight. The section was washed with PBS solution
containing 0.05% Tween 20 for 15 min, three times, and covered with the
secondary £uorescent antibody solution for 1 h at room temperature. Then
the section was washed with PBS solution including 0.05% Tween 20 for
15 min, three times, and mounted withVectashield (Vectashield with 4, 6-
Diamidine-2 phenylindole dilactate (DNA staining) (Dapi), Vector
Laboratories, Inc., Burlingame, California). The section was observed and
photographs were taken within 6 h.
Epidermal hyperplasia induced by barrier disruption under low
humidity Animals were kept separately in 7.2 liter cages in which the
relative humidity was maintained at less than 10% with dry air as
described previously (Denda et al, 1998b). The temperature was 22 to
251C, and fresh air was circulated 100 times per hour. Six to eight animals
were used to evaluate each treatment. Animals were kept out of the direct
stream of air. During the experiments, the animal’s behavior was not
restricted. The level of NH3 (ammonia) was always below 1 p.p.m.
Animals were ¢rst kept in dry conditions for 48 h and then both sides of
the £ank skin were treated with acetone-soaked cotton balls, as described
previously (Denda et al, 1998c). The procedure was terminated whenTEWL
reached 2.5 to 3.5 mg per cm2 per h. Immediately after the barrier
disruption, 100 mL of reagents aqueous solution (1 mM) was applied on
one side of the treated area.Water was applied on another side. Then the
animals were again kept in the dry condition for 48 h. After the
experiments, animals were euthanized with diethylether inhalation and
skin samples were taken from the treated area. One hour before the
euthanization, 20 mL per g body weight bromodeoxyuridine 10 mM
solution was injected intraperitoneally. Untreated control mice were also
treated with bromodeoxyuridine at the same time. After ¢xation with 4%
paraformaldehyde, full thickness skin samples were embedded in para⁄n,
sectioned (4 mm), and processed for hematoxylin and eosin staining. For the
assessment of DNA synthesis, the sections were immunostained with anti-
bromodeoxyuridine antibodies. On each section, ¢ve areas were selected at
random from one section; the number of immunostained cells per 1mm of
epidermis was counted and the mean value was calculated. Measurements
were carried out in an observer-blinded fashion.
Calcium dynamics in keratinocyte culture system First, we
incubated cells in a low-calcium medium (0.1 mM calcium, De¢ned
Keratinocyte SFM, Gibco BKL, Gland Island, NewYork) for at least 5 d
and used within 10 d. At the measurement, the keratinocytes showed 80
to 100% con£uency. Evaluation of [Ca2þ]i in cultured human
keratinocytes was carried out using fura-2 as described by Grynkiewicz
et al (1985) with minor modi¢cations (Koizumi and Inoue, 1997). Brie£y,
the culture medium was replaced with the bu¡ered saline solution,
containing 150 mM NaCl, 10 mM glucose, 25 mM HEPES, 5 mM KCl,
1.2 mM NaH2PO4, 1.2 mMMgCl2, and 1.8 mM CaCl2, adjusted pH 7.4 by
NaOH. Then, after adding fura-2 acetoxymethylester (Molecular Probes
Inc.) to the ¢nal concentration of 5 mM, cells were incubated for 45 min
at room temperature (21^231C). The cells were washed in saline and then
incubated for further 15 min to allow de-esteri¢cation of the loaded fura-2
acetoxymethylester. The coverslip was mounted on a £uorescence
microscope (IX70, TS Olympus, Tokyo, Japan) equipped with a 75 W
xenon-lamp and band-pass ¢lters of 340 nm and 380 nm wavelengths.
Measurements were carried out at room temperature. During the
experiments, £uorescence was observed in each cell and the ratio 340 nm/
380 nm was always more than 0.5. Imaging data, recorded by a high-
sensitive silicon intensi¢er target camera (C4742, Hamamatsu Photonics,
Hamamatsu, Japan) were regulated by a Ca2þ analyzing system (AQUA/
RATI01, Hamamatsu Photonics). For quanti¢cation of each treatment, we
used three di¡erent culture systems to con¢rm the reproducibility.
Statistics The results are expressed as the mean7SD. Statistical di¡eren-
ces were determined byANOVA test (Fisher’s protected least signi¢cant di¡erence).
RESULTS
Figure 1 shows the e¡ects of topical application of b-adrenergic
receptor agonists and antagonists on the skin barrier repair rate
Figure1. Topical application of an b2-adrenergic receptor agonist
(procaterol hydrochloride and alprenol) delayed and application of
an b2-adrenergic receptor antagonist (ICI-118 551) or b1,2 receptor
antagonist (clenbuterol) accelerated the skin barrier recovery after
barrier disruption. (A,B,C) These show the repair rate 1, 3, and 6 h after
treatment, respectively. The delay of barrier repair by the b2 receptor ago-
nist was blocked by the b2-adrenergic receptor antagonist. The barrier re-
covery rate was una¡ected by the topical application of an b1-adrenergic
receptor agonist or antagonist. Two points were measured on one side of
the £ank of hairless mice.Twelve mice were used for the water-treated con-
trol. Four mice were used for each treatment.Vertical axis shows the barrier
recovery percent. Error bars show SD. nnnpo 0.0001
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after tape stripping. Neither the b1 receptor agonist (xamoterol
hemifumarate) nor b1 receptor antagonist (betaxolol hydrochlor-
ide) a¡ected the recovery rate. The b2 agonist (procaterol hydro-
chloride and alprenolol) delayed barrier repair, and the b2
antagonist (ICI-118551) blocked the delay. Moreover, ICI-118551
or clenbuterol (b1,2 antagonist) alone accelerated barrier recovery
signi¢cantly. Twenty-four hours after tape stripping, no signi¢-
cant change was observed between the groups. These results sug-
gest the existence of an endogenous ligand of the b2 receptor in
the epidermis after barrier disruption. Neither a1-adrenergic an-
tagonist (corynanthin) nor a2 antagonist (rauwolscine hydro-
chloride) a¡ected barrier recovery (Fig 2).
Immunoreactivity against anti-b2 receptor antibody was ob-
served throughout the living layer of the epidermis (Fig 3A,
merged image with Dapi and Nomarski di¡erential interference
microscope: Fig 3B). The immunoreactivity was blocked by the
blocking peptide (Fig 3C, merged image with Dapi and No-
marski: Fig 3D). These results suggest the localization of b2-
adrenergic receptors in the epidermis.
Topical application of verapamil or nifedipine, both antago-
nists of the voltage-gated calcium channel, completely blocked
the delay of barrier repair induced by procaterol hydrochloride,
an b2-adrenergic agonist (Fig 4). This suggests an association of
the voltage-gated calcium channel on the alteration of the barrier
repair rate induced by the b2-adrenergic agonist. To con¢rm the
contribution of the voltage-gated calcium channel on barrier
homeostasis, we applied the channel activator, FPL64176, after
tape stripping. As shown in Fig 5, topical application of
FPL64176, signi¢cantly delayed the barrier repair rate.
Alterations of intracellular calcium concentration after the ap-
plication of procaterol hydrochloride alone, with ICI-118551, ver-
apamil, or with nifedipine in cultured human keratinocytes are
Figure 2. The barrier recovery rate was not signi¢cantly a¡ected by the topical application of a1-adrenergic receptor antagonist (corynathin)
and a2-adrenergic receptor antagonists (rauwolscine).Two points were measured on one side of the £ank of the hairless mice. Four mice were used for
each treatment including water-treated control. (A,B,C) These show the repair rate 1, 3, and 6 h after treatment, respectively.Vertical axis shows the barrier
recovery percent. Error bars show SD.
Figure 3. Immunoreactivity against b2-adrenergic receptor polyclonal antibody was observed in the hairless mouse epidermis (A, red col-
or).Merged image with Nomarski microscopic observation and DAPI staining (blue color) is shown in (B). The immunoreactivity against the b2-adrener-
gic receptor antibody was blocked by a blocking peptide (C, merged image with DAPI and Nomarski: D). Bars¼10 mm.
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shown in Fig 6. The intracellular calcium increase by procaterol
hydrochloride and pretreatment with ICI-118551, verapamil, or
nifedipine blocked the increase. In each case, we ¢rst applied each
reagent, and 30 s later, we applied procaterol hydrochloride. The
levels of intracellular calcium even decreased by the treatments
with b2 receptor antagonist or calcium channel blocker.These re-
sults suggest the existence of other endogenous adrenergic recep-
tor ligands. The quanti¢ed results are shown in Fig 6(I).
Under a low environmental humidity, an epidermal hyperpla-
sia was obviously induced by acetone treatment (Denda et al,
1998c). (A) shows the e¡ect of topical application of b2 agonist,
antagonist, and verapamil on epidermal hyperproliferation. The
b2 antagonist reduced the epidermal hyperproliferative response,
whereas b2 agonist on the hyperproliferation enhanced the
response. The e¡ect of b2 agonist on the hyperproliferation
blocked by verapamil. Representative photographs are shown in
Fig 7(B^F).
DISCUSSION
Adrenergic receptors were classi¢ed into two families, a and b
(Watson and Arkinstall, 1994). Previously, the existence of adre-
nergic receptors in epidermal keratinocytes was suggested by
autoradiographic mapping in human skin and the result showed
the localization of b2 receptors throughout the epidermis but not
b1 receptors (Steinkraus et al, 1996). Koizumi et al (1991) demon-
strated that there were increases of intracellular calcium concen-
tration in the human keratinocyte by epinephrine, norepine-
phrine, and isoproterenol. On the other hand, agonists of a1-
and a2-adrenergic receptors (clonidine and salbutamol) did not
increase the intracellular calcium concentration of keratinocytes.
They also demonstrated that the increase by epinephrine was
blocked by propranolol (b antagonist), but not by prazosin (a1
antagonist) and yohimbine (a2 antagonist). This study showed
responses in barrier recovery against b2 agonist and antagonist
but not against b1 agonist and antagonist. Antagonists of a1 and
a2 receptors did not a¡ect the barrier recovery rate. These results
suggest that mainly b2-adrenergic receptors are localized in the
epidermis and play an important part in the calcium dynamics
and barrier homeostasis of epidermal keratinocytes.
In this study, application of a b2 receptor antagonist alone ac-
celerated barrier recovery. This result suggested an increase of en-
dogenous adrenergic receptor agonist in the epidermis after
barrier disruption. Keratinocytes have the capacity for generating
catecholamines (Schallreuter, 1997). Epinephrine and other cate-
cholamines might mediate the signal not only from the sympa-
thetic nervous system but also in autocrine regulation among
epidermal keratinocytes.
We have previously demonstrated that a psychologic stress de-
layed the skin barrier recovery rate after its damage in hairless
mice skin (Denda et al, 1998a, 2000b). The e¡ect of psychologic
stress on barrier homeostasis has also been observed in human
skin (Denda et al, 2000c; Garg et al, 2001).We demonstrated that
the serum glucocorticoid level was associated with barrier home-
ostasis (Denda et al, 2000b). Takahashi and Iizuka (1991) reported
that glucocorticoids in£uenced the expression of b2-adrenergic
receptor in keratinocytes. The adrenergic system is also related to
the psychologic condition (Lorimer et al, 1976). The dynamics of
epinephrine and norepinephrine in the epidermis under di¡erent
Figure 4. The delay of the barrier repair induced by topical application of b2 agonist (procaterol hydrochloride) was blocked by the pretreat-
ment with verapamil or nifedipine, both voltage-gated calcium channel blocker.Two points were measured on one side of the £ank of the hairless
mice. Four mice were used for each treatment including water-treated control. (A,B,C) These show the repair rate 1, 3, and 6 h after treatment, respectively.
Vertical axis shows the barrier recovery percent. Error bars show SD.
Figure 5. Topical application of voltage-gated calcium channel activator,
FPL64176, after tape stripping, signi¢cantly delayed the barrier recovery.
Vertical axis shows the barrier recovery percent. Error bars show SD.
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Figure 6. Application of b2-adrenergic receptor agonist (procaterol hydrochloride) increased intracellular calcium concentration in the cul-
tured human keratinocytes and the increase was blocked by the pretreatment with b2-adrenergic receptor antagonist (ICI-118 551) or vera-
pamil and nifedipine, voltage-gated calcium channel blocker. (A^D) These show the calcium concentration in arti¢cial color.The colors blue, green,
yellow, and red indicate increasing concentration in this order. (E) This shows the results for 2.5 min after the application of b2-adrenergic receptor agonist
on the cells shown in (A). The calcium level increased in most of the keratinocytes. The intracellular calcium increase by procaterol hydrochloride was
blocked by pretreatment with ICI-118551 (F), verapamil (G), or nifedipine (H). In each cases, we ¢rst applied ICI-11851,verapamil, or nifedipine and 30 s
later, we applied procaterol hydrochloride. The levels of intracellular calcium even decreased by the treatments. The quanti¢ed results of these observations
are shown in (I). Application of b2-adrenergic receptor agonist signi¢cantly increased the intracellular calcium and pretreatment with ICI-118551 (b2 re-
ceptor antagonist) or verapamil (voltage-gated calcium channel blocker) blocked the increase.Vertical axis shows the ratio of the £uorescent intensity for
emission at 340 nm to that at 380 nm.
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psychologic conditions have not been clari¢ed; however, the
adrenergic metabolism might also be an important mediator be-
tween emotional condition and epidermal barrier function.
Activation of b receptor increases cyclic adenosine monopho-
sphate via Gs protein and also opens the voltage-gated calcium
channel (Keef et al, 2001). An increase of the intracellular calcium
concentration of keratinocytes by the application of b2 agonist
might be induced by the calcium in£ux through the calcium
channel. The cascade between the b2 receptor and voltage-gated
calcium channel in the keratinocyte has not been clari¢ed. Koizu-
mi et al (1997) have demonstrated that epinephrine and proprano-
lol increased protein kinase C activity, and suggested an
association of cyclic adenosine monophosphate as a second mes-
senger in the protein kinase C activation process. Zhou et al (1997)
have demonstrated that activation of the b2-adrenergic receptor
increased intracellular calcium in cardiac myocytes. They showed
that the process was mediated by cyclic adenosine monopho-
sphate and it opened the voltage-gated calcium channel. In kera-
tinocytes, cyclic adenosine monophosphate might also mediate
the intracellular calcium concentration through the voltage-gated
calcium channel. b2-adrenergic receptor is also associated
with the Naþ permeable channel (Marunaka et al, 1999) or en-
hancement of calcium release from the reticulum (Zhou et al,
1999). These phenomena might also be related to epidermal
homeostasis.
The ¢rst stage of the barrier recovery process after acute dis-
ruption is lipid-containing lamellar body secretion into the
intercellular domain between the stratum corneum and stratum
granulosum (Elias and Feingold, 2001). Then, a series of lipoge-
netic processes, lipid synthesis, and lipid processing, starts several
hours after barrier disruption (Elias and Feingold, 2001). In this
study, alteration of barrier recovery was observed within 1 h after
barrier disruption. Menon et al (1994) demonstrated that the la-
mellar body secretion was perturbed by the increase of calcium
in the epidermis. Both b2-adrenergic receptor agonist and an-
tagonist might a¡ect the lamellar body secretion and also, conse-
quently, barrier homeostasis.
Recently, we demonstrated that ligand-gated ion channels ori-
ginally found in the nervous system, were associated with barrier
homeostasis (Denda et al, 2002a, b). Agonists of a purinergic re-
ceptor that includes a cation channel, increased the intracellular
calcium concentration in keratinocytes and delayed skin barrier
recovery after barrier disruption (Denda et al, 2002a). On the
other hand, GABA(A) receptor is a chloride channel and its ago-
nist increased the chloride in£ux in keratinocytes and accelerated
barrier repair (Denda et al, 2002b). The ligand-gated ion-channel,
which plays an important part in the nervous system was also as-
sociated with the cutaneous barrier function. In this study, adre-
nergic receptors, which do not have any ion-channel function
also might play an important part in the skin barrier function.
Figure 7. Topical application of b2-adrenergic antagonist, ICI-118551, reduced the epidermal hyperproliferative response induced by acetone
treatment under low environmental humidity (Fig 5A). On the other hand, b2-adrenergic agonist enhanced the epidermal hyperproliferation and the
e¡ect was blocked by verapamil (A). (B) This shows the representative skin section of untreated control of hairless mice.With acetone treatment under low
humidity, obvious epidermal hyperplasia was induced when we applied water only (C). The epidermal hyperplasia partially reduced by 1 mM ICI-118551,
b2-adrenergic receptor antagonist (D). Application of b2-adrenergic receptor agonist (procaterol hydrochloride) enhanced the hyperproliferative response
(E) and the e¡ect was blocked by verapamil (F). Dark cells are bromodeoxyuridine positive cells. Bars¼ 20 mm.
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Not only ionotropic receptors, but also metabotropic receptors,
well known as a device of the nervous system, might play an im-
portant part in skin barrier homeostasis or other epidermal
homeostasis.
In this study, epidermal hyperproliferation, induced by acetone
treatment was also reduced by the b2-adrenergic antagonist. Pur-
inergic receptor antagonist and GABA also prevented the epider-
mal hyperplasia (Denda et al, 2002a, b). Applications that could
accelerate the barrier repair tend to prevent the epidermal hyper-
plasia (Denda et al, 1997; Ashida and Denda, 2001). Barrier dys-
function induced epidermal DNA synthesis (Proksch et al, 1991);
thus, this tendency might be due to the barrier repair. The cal-
cium in£ux, however, is also associated with keratinocyte prolif-
eration, di¡erentiation, and cytokine generation (Yuspa et al,
1988).The reagents, which regulate ion £ux in keratinocytes might
regulate a variety of aspects of the pathology of the epidermis.
In conclusion, an b2-adrenergic receptor agonist delayed skin
barrier recovery after barrier disruption, whereas an antagonist
accelerated skin barrier recovery after barrier disruption. They
also altered the intracellular calcium concentration in the cultured
keratinocytes.Verapamil and nifedipine blocked the delay of bar-
rier repair and an increase of calcium by the agonist. These results
suggest that the b2-adrenergic receptor was speci¢cally associated
with the epidermal barrier homeostasis through the voltage-
gated ion channel.
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